Diabetes Trials Unit
The Diabetes Trials Unit (DTU) is a clinical trials unit specialising in performing local, national and multinational clinical trials related to treating and managing diabetes and other cardiometabolic and related conditions. We work collaboratively with researchers and organisations to support trials and other studies.
Director
-
Amanda Adler
Professor of Diabetic Medicine and Health Policy
What's new
First patient randomised on the ISAP study
18 August 2023
UKPDS Outcomes Model Version 2.2 Released
26 May 2023
Latest publications
-
Aetiology of Type 2 diabetes in people with a 'normal' body mass index: Testing the Personal Fat Threshold Hypothesis.
Journal article
Taylor R. et al, (2023), Clin Sci (Lond)
-
Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.
Journal article
Regan JA. et al, (2023), JCI Insight
-
Sumatriptan, a serotonin 5HT1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial
Journal article
Golubic R. et al, (2023), Diabetes, Obesity and Metabolism
-
Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
Journal article
Hundertmark MJ. et al, (2023), Circulation, 147, 1654 - 1669
-
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
Journal article
Bethel MA. et al, (2023), Cardiovasc Diabetol, 22
|
